30.08.2016 Views

Major Depressive Disorder (MDD) Treatment Market Value Share, Supply Demand 2016-2026

Future Market Insights has announced the addition of the “Major Depressive Disorder (MDD) Treatment Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026” report to their offering.

Future Market Insights has announced the addition of the “Major Depressive Disorder (MDD) Treatment Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026” report to their offering.

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Global <strong>Major</strong><br />

<strong>Depressive</strong> <strong>Disorder</strong><br />

(<strong>MDD</strong>) <strong>Treatment</strong><br />

<strong>Market</strong><br />

<strong>Share</strong>, Global Trends,<br />

Analysis, Research, Report,<br />

Opportunities,<br />

Segmentation and Forecast,<br />

<strong>2016</strong>-<strong>2026</strong><br />

Future <strong>Market</strong> Insights<br />

www.futuremarketinsights.com<br />

sales@futuremarketinsights.com


Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting<br />

services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />

technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.<br />

We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.<br />

Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and<br />

Retail.<br />

We have a global presence with delivery centers across India specializing in providing global research reports and country<br />

research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />

We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for<br />

our client.<br />

Research Capabilities<br />

• Customized Research<br />

• Syndicated Research<br />

• Investment Research<br />

• Social Media Research<br />

Sector Coverage<br />

• Automotive and Transportation<br />

• Electronics, Semiconductor, and ICT<br />

• Retail and Consumer Products<br />

• Industrial Automation and Equipment<br />

• Chemicals & Materials<br />

• Food and Beverages<br />

• Services and Utilities<br />

• Energy, Mining, Oil, and Gas<br />

Customized<br />

Research<br />

Syndicated<br />

Research<br />

Investment<br />

Research<br />

Social Media<br />

Research<br />

Subscription Information<br />

For detailed subscription information please contact<br />

Hari. T (Sr. Manager - Global Business Development)<br />

T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />

Email: hari.t@futuremarketinsights.com


Report Description<br />

<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) is one of the most common mental disorder characterized by<br />

persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep<br />

and normal activities. <strong>MDD</strong> is also referred as clinical depression, major depression, and<br />

unipolar depression or as recurrent depression. The common symptoms associated with this<br />

disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of<br />

worthlessness and reduced ability to think. Increasing number of patients suffering from <strong>MDD</strong><br />

has grabbed the attention of <strong>MDD</strong> drugs manufacturer to invest into <strong>MDD</strong> treatment market.<br />

<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Drivers and Restraints<br />

Work life imbalances due to change in life style, and increase in <strong>MDD</strong> patient pool are the key<br />

drivers expected to drive the <strong>MDD</strong> treatment market over the forecasted period. Partnerships<br />

for co-development and co-marketing of <strong>MDD</strong> drugs among the drug manufactures across the<br />

globe, development of new drugs, and adequate government reimbursement policies have also<br />

fueled the growth of <strong>MDD</strong> treatment market. However, stringent regulations imposed by various<br />

governments for new drug approval, patent expiries of some blockbuster drugs, risk of<br />

complications with other medications, and related side effects of <strong>MDD</strong> drugs may hinder the<br />

growth of <strong>MDD</strong> treatment market over the forecasted period.<br />

Request for sample report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1314


Report Description<br />

•<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Segmentation<br />

•The global <strong>MDD</strong> treatment market is segmented based on drug type used for the<br />

treatment of <strong>MDD</strong>.<br />

•Antidepressants<br />

• Selective Serotonin Reuptake Inhibitors (Ssris)<br />

• Dopamine Norepinephrine Reuptake Inhibitor<br />

• Serotonin Norepinephrine Reuptake Inhibitor<br />

• Serotonin Modulators<br />

• Norepinephrine-Serotonin Modulator<br />

• Tricyclics and Tetracyclics<br />

• Monoamine Oxidase Inhibitors (MAOIs)<br />

• Irreversible, non-selective inhibitors<br />

• Phenelzine<br />

• Tranylcypromine<br />

• Isocarboxazid<br />

• Irreversible, MAO B selective inhibitor<br />

• Selegiline transdermal<br />

• Reversible, MAO A selective inhibitor<br />

• Moclobemide


Report Description<br />

Atypical antidepressants<br />

Antipsychotics<br />

<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Overview<br />

At present, antidepressants are most commonly used drugs for the treatment of <strong>MDD</strong>,<br />

and has the largest market segment. <strong>Major</strong> brands of SSRI’s include Citalopram,<br />

Escitalopram, Fluoxetine, Paroxetine, and Sertraline. Bupropion, Mirtazapine, and<br />

Razodone, are atypical antidepressants frequently used for the treatment of <strong>MDD</strong>. <strong>Major</strong><br />

brands of antipsychotics includes Resperidone, Olanzapine, Quetiapine, Ziprasidone, and<br />

Aripiprazole. Global <strong>MDD</strong> treatment market is expected to grow with a healthy CAGR<br />

owing to increase in <strong>MDD</strong> patient pool over the forecast period.<br />

Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1314<br />

<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Region-wise Outlook<br />

Geographically, North America market is estimated to hold maximum market revenue<br />

share in global <strong>MDD</strong> treatment market owing to increase in number of patients suffering<br />

from <strong>MDD</strong>, and advancement in technology to develop new therapeutic drugs and<br />

followed by Europe and Asia-Pacific respectivily. The market in Asia-Pacific is expected to<br />

expand at a significant CAGR over the forecasted period due to increasing awareness for<br />

depression conditions and complications associated with it. <strong>MDD</strong> treatment market is<br />

expected to register healthier CAGR in emerging markets such as India, China, and Brazil<br />

compared to other developed regions in the world.


Report Description<br />

<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Key Players<br />

Key companies operational in <strong>MDD</strong> treatment market are Eli Lilly and Company,<br />

Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc,<br />

Sanofi S.A., Shire plc, Novartis AG, Janssen Pharmaceutical, Inc., and others.


Thank You!<br />

To know more about us, please visit our website:<br />

www.futuremarketinsights.com<br />

For sales queries or new topics email us on:<br />

sales@futuremarketinsights.com<br />

Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />

Valley Cottage, NY 10989, United States<br />

T: +1-347-918-3531 | D: +1-845-579-5705

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!